Navigation Links
Gen-Probe Reports Financial Results for Second Quarter 2009
Date:7/30/2009

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under "Updated 2009 Financial Guidance," are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, regulatory approvals, future milestone payments, growth opportunities, and plans and objectives of management are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2009 financial targets, (ii) the risk that we may not integrate acquisitions, such as Tepnel, successfully, (iii) the possibility that the market for the sale of our new products, such as our TIGRIS system, PROCLEIX ULTRIO assay and PROGENSA PCA3 assay, may not develop as expected, (iv) the enhancement of existing products and the development of new products, including products, if any, to be developed under our industrial collaborations, may not proceed as planned, (v) the risk that products, including the investigational PROGENSA PCA3 assay for which we expect to begin clinical trials shortly, may not be approved by regulatory authorities or commercially available in the time frame we anticipate, or at all, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collabora
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Gen-Probe to Webcast Two Upcoming Investor Presentations
2. Gen-Probe Reports Financial Results for First Quarter 2009
3. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
4. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
5. Tepnel Shareholders Approve Acquisition by Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
7. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
8. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
9. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
10. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
11. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... 2014 Parker Waichman LLP, a national ... comments on a recent tobacco lawsuit in which a ... billion in punitive damages. Cynthia Robinson brought the lawsuit ... case is Cynthia Robinson v. R.J. Reynolds Tobacco Company ... Circuit Court, Escambia County, Florida; Case Number 2008 CA ...
(Date:7/25/2014)... nearly 27,000 older adults on five continents found that ... on a simple test that measures how fast people ... tested positive for pre-dementia were twice as likely as ... led by scientists at Albert Einstein College of ... Center , was published online on July 16, 2014 ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As thousands ... in U.S. courts, Bernstein Liebhard LLP notes that the ... by the consumer advocacy group, Public Citizen, to order ... a letter dated May 1, 2014, and released to ... group’s petition for a ban on the marketing of ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4
... may be at increased risk of experiencing a life-threatening ... with low POD had significantly more emergency department visits, ... 2 year study period than those with normal dyspnoea ... to be older, female and generally had suffered from ...
... well perceived that smoking accelerates the risk of heart disease, ... capacity for the development of a heart attack.This is because ... immediate impact on the cardiovascular system.// ,In a study ... smoked a cigarette within six hours of developing symptoms had ...
... Johns Hopkins University School of Medicine have recently found that ... brain that lets us stop smelling something, even though the ... recent issue of the journal Science show that a protein ... main job of these reurons is to detect smells and ...
... bring to notice that sensible drinking could reduce their risk ... of excess. In a new leaflet, the Stroke Association says ... caused by blood clots blocking arteries - which account for ... ,Alcohol thins the blood, so can prevents the formation ...
... a leafy plant native to the South Sea Islands. It ... cases of liver diseases. The herb is commonly used by ... stress and muscle spasms. According to experts, the herb behaves ... not chemically related. ,Benzodiazepines have been shown to be ...
... first isolated a decade ago at Johns Hopkins, may ... study shows that the compound, sulphoraphane, helps cells defend ... and toxic molecules called oxidants.// , Unlike standard anti-oxidants ... combat, broccoli’s compound is a covert operative that works ...
Cached Medicine News:
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
... Diagnostic Workstation Software offers a complete ... digitally stores many different diagnostic tests ... open-architecture products in mind, our software ... (using ActiveX controls), networking, central database ...
... is engineered to set a new standard ... is enter the patient demographics, select auto ... Windows based system uses the latest in ... versatility of the IQmark Holter algorithm. Simple, ...
... remarkable skin Transformation in less than an hour ... peels or other superficial procedures, the Obagi Blue ... yours. Based on your patients' particular skin needs, ... Acid (TCA) peels and number of coats applied. ...
... Smoothie is deliciously refreshing scrub ... the use of a gentle ... exfoliate the skin to restore ... irritation. This light chemical peel ...
Medicine Products: